Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Controlled Study to Produce Guidelines for Integrating Prism for MDD Therapy (Reward System [RS] Upregulation) and to Demonstrate Its Superiority Over Sham Therapy

NCT06982820 is registered in ClinicalTrials.gov with GrayMatters Health Ltd. as lead sponsor.

NCT NCT06982820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06982820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Controlled Study to Produce Guidelines for Integrating Prism for MDD Therapy (Reward System [RS] Upregulation) and to Demonstrate Its Superiority Over Sham Therapy
Lead sponsor
GrayMatters Health Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
June 25, 2025
Completion date
August 30, 2027
Enrollment
170 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major